The US plan to have a coronavirus vaccine ready by the end of the year, unveiled on 15 May by President Donald Trump, has many wondering if the race to develop such a product is heating up considerably, given that on 18 May one of the leading developers, US firm Moderna Inc., disclosed positive preliminary results from a Phase I trial for its mRNA-based vaccine.
The recent developments are further stirring up a debate over whether the US is getting ahead of China, which started...